Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in postmortem blood specimens using infectious disease assays licensed for cadaveric donor screening
Tóm tắt
Evaluation of assay performance on postmortem blood specimens (obtained after cessation of the heartbeat) presents unique scientific and regulatory challenges. In the United States, assay performance is evaluated in part by spiking postmortem specimens.
Fifty‐four specimens obtained from decedents known to be infected with human immunodeficiency virus (
For each disease, >95% of subjects who were reported to have an infection at the time of death had a positive test result on at least one of the donor screening assays for that infection.
Licensed donor screening tests were positive on postmortem specimens obtained within 24 hours of death from individuals dying with
Từ khóa
Tài liệu tham khảo
Food and Drug Administration (US).Guidance for Industry: Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells Tissues and Cellular and Tissue‐Based Products (HCT/Ps). Dated November2004.http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073972.htm. Accessed December 15 2017.
Health Canada.Guidance for Manufacturers of Human Immunodeficiency Virus (HIV) Test Kits intended to be used in the Laboratory. Dated2011.http://www.hc-sc.gc.ca/dhp-mps/md-im/applic-demande/guide-ld/md_gd_hiv_im_ld_vih-eng.php. Accessed December 15 2017.
The Advisory Committee on the Safety of Blood Tissues and Organs (UK).Guidance on the Microbiological Safety of Human Organs Tissues and Cells used in Transplantation;2011.https://www.gov.uk/government/publications/guidance-on-the-microbiological-safety-of-human-organs-tissues-and-cells-used-in-transplantation. Accessed December 15 2017.
European Parliament and the Council of the European Union.Directive 2004/23/EC of The European Parliament and of The Council of 31 March 2004 on setting standards of quality and safety for the donation procurement testing processing preservation storage and distribution of human tissues and cells.https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=4&ved=0ahUKEwj2oI_g38PKAhWLbD4KHQF3C0AQFggxMAM&url=http%3A%2F%2Fhpscreg.eu%2Fdocs%2Fdownloads%2Fl_29420061025en00320050.pdf&usg=AFQjCNE20tdr33tUcf7PxmPaHDmsiOS3Fg&sig2=L1iYcT-4GDZ0PU_MthXl51w&cad=rja. Accessed December 15 2017.
European Parliament and the Council of the European Union.Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation procurement and testing of human tissues and cells.http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:038:0040:0052:EN:PDF. Accessed December 15 2017.
Therapeutic Goods Administration (Australia).Therapeutic Goods Order No. 88 – Standards for donor selection testing and minimising infectious disease transmission via therapeutic goods that are human blood and blood components human tissues and human cellular therapy products.https://www.comlaw.gov.au/Details/F2013L00854. Accssed December 15 2017.
Food and Drug Administration (US).Eligibility determination for donors of human cells tissues and cellular and tissue‐based products; guidance for industry. Dated 8/2007.
Food and Drug Administration (US).Testing HCT/P Donors for Relevant Communicable Disease Agents or Diseases.http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/TissueSafety/ucm095440.htm. Accessed December 29 2016.